Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Tech Master who wrote (529)	5/4/1998 4:25:00 PM
From: Andreas Helke	Read Replies (3) \| Respond to of 2135

I know that Entremed is ridiculously expensive if you measure it by the usual biotech valuating yardsticks. But maybe Entremed is among the companies where those measures do not apply. If we knew that Endosatin works as well in humans as it does in mice the shares would be worth several hundred dollars. Because we don't know yet the shares are still much cheaper than that. After I read the november Nature paper about the Endostatin results in mice I immediately recognized that I simply could not afford to not have a position in this companies stock. I have too much money in other cancer biotech companies. Many of their drugs may become obsolete if Endostatin works as well in humans as it does in mice. If more biotech investors recognize that they can't afford not to own Entremed the available supply of shares won't go far and the stock will stay expensive. I think it is very likely that the stock will fall seriously below the current level but I don't think that I will sell my current shares because I don't want to risk to be left behind without Entremed shares. If it turns out that Endostatin does not work in humans the investment will be a bust but that is the risk of early development stage biotechs with a very promising drug candidate. Andreas